TPST-1495
1 abstract
Abstract
A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.Org: University of Okahoma Health Sciences Center, Carolina BioOncology Institute, Sarah Cannon Research Institute/Tennessee Oncology, University of Michigan, START Midwest, Grand Rapids, MI,